Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12788565 | 0.79 | CA12 (0.46) | MMP1MMP2CA1CA2CA12 | |
| SCHEMBL18287166 | 0.75 | ALDH1A1 (0.41) | POLBLMNAMAPK1SMN1; SMN2PKM | |
| SCHEMBL18287158 | 0.73 | TAS1R3 (0.34) | CA1CA2POLBTAS1R3TAS1R1 | |
| SCHEMBL3240918 | 0.73 | MMP8 (0.34) | MMP1MMP2MMP8SMN1; SMN2MMP3 | |
| SCHEMBL5807533 | 0.73 | PIK3CD (0.33) | MMP8LMNATDP1PIK3CD | |
| SCHEMBL18287165 | 0.72 | MLYCD (0.40) | MMP1MMP2CA1CA2MMP8 | |
| SCHEMBL18287159 | 0.71 | FAAH (0.34) | — | |
| SCHEMBL15355952 | 0.71 | CA12 (0.39) | MMP1MMP2CA1CA2CA12 | |
| SCHEMBL9911449 | 0.70 | CA1 (0.52) | MMP1MMP2CA1CA2CA12 | |
| SCHEMBL18287164 | 0.70 | EPHX1 (0.39) | MMP8POLBPKMPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981862-B2 | Physiological cooling compounds | SYMRISE, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10173966-B2 | Physiological cooling compounds | SYMRISE, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180179147-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | SYMRISE, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179147-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | SYMRISE, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20160355463-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | SYMRISE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160355463-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | SYMRISE, INC. | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981862-B2 | Physiological cooling compounds | TAS2R8, TAS2R3, TAS2R1 | MMP1 4814/4885MMP2 4439/4885CA1 3222/4885 |
| US-10173966-B2 | Physiological cooling compounds | TAS2R8, TAS2R3, TAS2R1 | MMP1 4814/4885MMP2 4439/4885CA1 3222/4885 |
| US-20160355463-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | TAS2R8, TAS2R3, TAS2R1 | MMP1 4814/4885MMP2 4439/4885CA1 3222/4885 |
| US-20180179147-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | TAS2R8, TAS2R3, TAS2R1 | MMP1 4814/4885MMP2 4439/4885CA1 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.